Clinical trials: Morning Sickness
Hyperemesis Gravidarum
Pregnancy Specific Nausea Questionnaire (PUQE) Translated and Tested in Norwegian
Nausea in early pregnancy (emesis gravidarum) is very common but most often self-limiting. Hyperemesis gravidarum; where nausea and vomiting is severe and protracted is potentially dangerous for the woman and her foetus and…
- Trial name
- PUQE-N (NCT01836835)
- Testing
- Pregnancy Unique Questionnaire of Emesis (PUQE), 24 hours self-reported nutritional intake form
- Where
- 2 sites in Norway
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
Morning Sickness
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
The primary objective of this study is to compare the efficacy of Bonjesta for the treatment of nausea and vomiting of pregnancy (NVP) in pregnant adolescents aged 12 to 17 years with placebo.
- Trial name
- NCT05289557
- Testing
- Bonjesta
- Where
- 10 sites in United States
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- Duchesnay Inc.
Hyperemesis Gravidarum, Temperament
Assessment of the Relationship Between Affective Temperament and the Severity of Nausea and Vomiting in Early Pregnancy
In this study, the investigators aimed to research the relationship between affective temperament with the severity of the symptoms of nausea and vomiting in early pregnancy.
- Conditions
- Hyperemesis Gravidarum, Temperament, Morning Sickness
- Trial name
- NCT02541682
- Testing
- TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)
- Where
- Turkey (Türkiye)
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Mustafa Kemalpasa Government Hospital
Morning Sickness
A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
The primary objective of this study is to compare the efficacy of Diclegis for the treatment of nausea and vomiting of pregnancy (NVP) in pregnant adolescents aged 12 to 17 years with placebo.
- Trial name
- PED-301 (NCT02045901)
- Testing
- Diclegis
- Where
- 8 sites in United States
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Duchesnay Inc.